Crossover Study to Compare Pharmacokinetic Property of SYP-1512 Tab and Revlimid Cap in Healthy Male Volunteers
Status:
Completed
Trial end date:
2016-10-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the pharmacokinetics equivalence and safety by
comparing pharmacokinetics characteristics between the SYP-1512 Tab and Revlimid cap (25mg)
when administered a single-dose to healthy male volunteers.